

October 3, 2023

Press Release

European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)

EFPIA Japan Announces Winners for 6th “PASE AWARD” Patient Organization Support Program

TOKYO – 3rd October 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA Japan, Chair: Takahiko Iwaya) announced the following award winners for the 6th PASE AWARD, a Patient Advocacy Support program by EFPIA Japan.

PASE AWARD is a patient organization support program established in 2017 with the goal of encouraging patient group activities in Japan and developing a better healthcare environment surrounding patients by reflecting patients’ voices appropriately in the healthcare system.

6th PASE AWARD Winners

Award	Name of the award organization	Awarded Implementation Plan [*]	Grant JPY
Grand Award	General Incorporated Association CSR Project	Universal cancer education through multilingual and multicultural learning materials, promotion of international exchange	500,000
Grand Award	Non-profit Organization NMOSD Japan	Improving quality of life in neuromyelitis optica patients by visualization	500,000
Grand Award	Non-profit Organization Ryoiku World	Developing an ‘Intractable Disease Persona Workshop’ to infer and think about the background and problems surrounding those affected	500,000
Honor Award	General Incorporated Association Team CML @Japan	Questionnaire survey of female CML patients who wish to conceive and have a child and raising awareness of the issue	150,000
Honor Award	Non-profit Organization Japan Aphasia Peer Circle	Production and distribution of ribbon badges to be worn by people with aphasia	150,000

Previously, the PASE AWARD was intended for officially registered non-profit patient organizations such as incorporated associations, foundations, and non-profit organizations. This year, EFPIA Japan has expanded the scope of applications to unincorporated patient organizations and called for entries under the theme of “improving the health and quality of life of patients” and received applications from a total of 20 organizations. After initial reviews

in writing and final reviews through presentations and questions and answers, three organizations were selected for the Grand Award, and two organizations were selected for the Honor Award.

The selection committee members for the final review are as follows.

Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)

Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)

Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)

Ms. Yuko Kidoguchi, EFPIA Japan Communications Committee Chair (AstraZeneca K.K.)

Mr. Daisuke Uchida, EFPIA Japan Governance and Legal Committee Chair (Sanofi K.K.)

Takahiko Iwaya, Chair of EFPIA Japan, commented, "I would like to thank all the patient organizations that applied for the 6th PASE AWARD. Patient organizations play a wide range of roles in shaping a better treatment environment for patients, and EFPIA Japan will continue to collaborate and interact with patient organizations."

The Awards Ceremony will be held at the Imperial Hotel on October 4th, and the organizations that receive the Grand Award will be asked to present their plan at the Ceremony.

About the EFPIA Japan Patient Association Program "PASE AWARD"

EFPIA Japan works with patients to support opportunities and activities that address patient needs and policy proposals. The PASE (Patient Advocacy Support by EFPIA Japan) AWARD was established in 2017 to encourage the patient group activities in Japan. Over the past 6 years, a total of 106 organizations have applied for a wide range of activity plans, and we provide a total of 1.8 million yen in grants to three organizations for Grand Awards and two organizations for Honor Awards.

See the link for more information about PASE.

<http://efpia.jp/pase/index.html>

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2022, combined sales from the member companies accounted for roughly 31% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to "Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines". EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations) (<http://www.efpia.eu>)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 40 leading pharmaceutical companies, and a growing number of small and medium sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop, and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.



European Federation of Pharmaceutical
Industries and Associations

Contact:

Hitoshi Fujita
EFPIA Japan Communications Committee
〒105-6333
1-23-1 Toranomom 1, Minato-ku, Tokyo
Toranomom Hills Mori Tower
Novartis Pharma K.K.
TEL: 090-9837-4326
Mail: hitoshi.fujita@novartis.com

Naomi Sakai (Person in charge of PASE)
EFPIA Japan Patient Committee